You are here: Industry Insights > Transcenta

News List

Transcenta Received IND Clearance from NMPA of its Anti-sclerostin Monoclonal Antibody TST002 prnasia
September 28, 2021
Transcenta Holding Limited ("Transcenta"), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics...
Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction prnasia
July 29, 2021
Transcenta Holding Limited, a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administration (FDA) has ...
Transcenta Announces First Patient Dosed in Global Phase I Clinical Trial of PD-L1/TGF-β Bi-functional Antibody TST005 prnasia
July 15, 2021
Transcenta Holding Limited announces that the first US patient has been dosed in the global Phase I clinical trial of PD-L1/TGF-β bi-functional antibody TST005.
Transcenta Announces NMPA Acceptance of IND Application of its Anti-Sclerostin Monoclonal Antibody TST002 prnasia
July 07, 2021
Transcenta Holding Limited announces that NMPA has accepted IND application of its anti-sclerostin monoclonal antibody TST002.
Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer prnasia
July 05, 2021
Transcenta Holding Limited announces that promising anti-tumor responses have been observed in the ongoing TST001 (anti-Claudin18.2 monoclonal antibody) trials.
Transcenta Announced Completion of First Patient Dosing in PET-CT Imaging Study of Radionuclide-Labeled CLDN18.2 Antibody prnasia
June 02, 2021
Transcenta Holding Limited announced completion of first patient dosing in PET-CT imaging study of radionuclide-labeled CLDN18.2 antibody.
Transcenta Announced the Results of the Phase I Clinical Study of PD-L1 Antibody MSB2311 with Advanced Solid Tumors and Hematological Malignancies prnasia
May 20, 2021
Transcenta Holding Limited, a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced that the updated Phase I clinical study (NCT04272944) data on the ...
Transcenta Announces Updated Clinical Data from Phase I Study of pH-Dependent PD-L1 Antibody MSB2311 to Be Presented at the 2021 ASCO Annual Meeting prnasia
May 14, 2021
Transcenta Holding Limited, a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that the updated phase I clinical data on the ...
Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005 prnasia
April 21, 2021
Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of ...
Transcenta Announced Successful First Patient Dosed in Phase I Clinical Study of TST001 Combined with CAPOX for the Treatment of Patients with First-line Locally Advanced Unresectable or Metastatic Ga prnasia
April 19, 2021
Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the first patient has been ...

Previous page 1 2 Next page